Achieve Life Sciences Inc (ACHV)
Achieve Life Sciences, Inc. is a late-stage pharmaceutical company focused on developing and commercializing cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. Cytisinicline is a plant-based alkaloid designed to act on nicotine receptors in the brain and help reduce the severity of nicotine withdrawal symptoms. The company has licensing and supply agreements with Sopharma AD and the University of Bristol. Achieve Life Sciences is headquartered in Bothell, Washington, and its common stock trades on the NASDAQ under the symbol ACHV.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ACHV
|
$4.37
|
-32.5% Downside
|
Overvalued
|
$13.80
|
113.1% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-12.8x
|
62.5x
|
—
|
640.6 M
|
653 M
|
2.3%
|
85.2%
|
0.3
|
—
|
87.2%
|
